Tag Archive for: M Ventures

Outrun Therapeutics launches with a $10m seed financing from M Ventures and MP Healthcare Venture Management to develop a protein stabilisation pipeline

Proprietary E3 ligase platform to enable protein stabilisation “at source”, thereby restoring the body’s sophisticated natural disease suppression processes Platform scales the assessment of E3 ligase targets while addressing the historic challenges of drugging these targets Pipeline of first-in-class, small molecule, E3 ligase inhibitors to stabilise proteins and treat disease in several therapeutic areas, including […]

Trends in life science investments – Top take-aways from Anglonordic

The first panel of the day, chaired by Mary Clark, our co-founder and CEO, saw a group of Europe’s leading investors – Hakan Goker, M Ventures; Maina Bhaman, Sofinnova Partners; Christian Elling, Lundbeckfonden; and Roel Bulthuis, Syncona – share sage advice for companies looking to raise funds, providing insights on the most important factors shaping […]

Can private markets continue to drive development in Life Sciences? – Insights from Optimum’s Healthcare Conference

We were proud to host a fantastic panel chaired by BioCentury’s European Editor Stephen Hansen with Soren Moller, Managing Partner of Novo Seeds; Karin Kleinhans, Partner of MRL Ventures Fund; Hakan Goker, Managing Director of M Ventures; Roel Bulthuis, Managing Partner at Inkef. This panel of Venture Capital (VC) investors discussed the strength of private […]

An Overview of Optimum’s 14th Annual Healthcare Investor Conference 2022

Two weeks ago, Optimum hosted its 14th Annual Healthcare Investor Conference and wow, what a fantastic event it was! After two years of disruption, we were delighted to be meeting again in person. While virtual meetings have been a fantastic boon during these difficult times, nothing can beat meeting and sharing ideas and opinions face-to-face, […]

How Early-stage VCs are Adjusting in a Bear Market

As part of a panel session, hosted by Stephen Hansen, at the Anglonordic Life Science conference on 5 May, Optimum’s clients explored the latest dynamics of syndicate building for early-stage VCs.